DFTX
Income statement / Annual
Last year (2025), Definium Therapeutics Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2025, Definium Therapeutics Inc.'s net income was -$183.79 M.
See Definium Therapeutics Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
12/31/2025 |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
08/31/2019 |
08/31/2018 |
08/31/2017 |
08/31/2016 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$527.00 K
|
$3.16 M
|
$0.00
|
$0.00
|
$0.00
|
$6.68 K
|
$6.68 K
|
$5.50 K
|
$0.00
|
| Gross Profit |
$0.00
|
-$527.00 K
|
-$3.16 M
|
$0.00
|
$0.00
|
$0.00
|
-$6.68 K
|
-$6.68 K
|
-$5.50 K
|
$0.00
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$117.67 M
|
$65.30 M
|
$48.96 M
|
$36.17 M
|
$34.79 M
|
$18.63 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| General & Administrative Expenses |
$48.64 M
|
$38.62 M
|
$41.74 M
|
$30.16 M
|
$59.07 M
|
$14.40 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$48.64 M
|
$38.62 M
|
$41.74 M
|
$30.16 M
|
$59.07 M
|
$14.40 M
|
$461.50 K
|
$855.26 K
|
$1.23 M
|
$111.25 K
|
| Other Expenses |
$0.00
|
-$527.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$166.31 M
|
$103.39 M
|
$90.70 M
|
$66.33 M
|
$93.85 M
|
$33.03 M
|
$461.50 K
|
$855.26 K
|
$1.23 M
|
$111.25 K
|
| Cost And Expenses |
$166.31 M
|
$103.92 M
|
$93.87 M
|
$66.33 M
|
$93.85 M
|
$33.03 M
|
$468.18 K
|
$861.94 K
|
$1.24 M
|
$111.25 K
|
| Interest Income |
$10.96 M
|
$11.56 M
|
$5.58 M
|
$1.50 M
|
$0.00
|
$0.00
|
$0.00
|
$4.00 K
|
$8.40 K
|
$1.20 K
|
| Interest Expense |
$5.48 M
|
$2.28 M
|
$920.00 K
|
$1.50 M
|
$359.00 K
|
$164.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$0.00
|
$527.00 K
|
$3.16 M
|
$3.18 M
|
$2.62 M
|
$206.30 K
|
$6.68 K
|
$6.68 K
|
$5.50 K
|
$0.00
|
| EBITDA |
-$178.31 M |
-$105.87 M |
-$92.57 M |
-$63.15 M |
-$91.24 M |
-$33.57 M |
-$1.11 M |
-$851.26 K |
-$1.51 M |
-$111.25 K |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
-$17.48 M
|
-$4.76 M
|
-$1.87 M
|
$9.54 M
|
-$339.00 K
|
-$907.00 K
|
-$647.63 K
|
$4.00 K
|
$8.40 K
|
-$68.65 K
|
| Income Before Tax |
-$183.79 M
|
-$108.68 M
|
-$95.73 M
|
-$56.80 M
|
-$94.19 M
|
-$33.94 M
|
-$1.12 M
|
-$857.94 K
|
-$1.23 M
|
-$179.90 K
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$1.16 M
|
$0.00
|
-$3.69
|
-$1.91
|
-$1.70
|
$0.00
|
| Net Income |
-$183.79 M
|
-$108.68 M
|
-$95.73 M
|
-$56.80 M
|
-$93.04 M
|
-$34.10 M
|
-$1.12 M
|
-$857.94 K
|
-$1.23 M
|
-$179.90 K
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-2.06 |
-1.54 |
-2.44 |
-1.53 |
-3.4 |
-1.92 |
-2.94 |
-2.74 |
-4.85 |
-2.24 |
| EPS Diluted |
-2.06 |
-0.15 |
-2.44 |
-1.53 |
-3.4 |
-1.92 |
-2.94 |
-2.74 |
-4.85 |
-2.24 |
| Weighted Average Shares Out |
$89.33 M
|
$70.46 M
|
$39.16 M
|
$30.86 M
|
$27.38 M
|
$17.75 M
|
$379.41 K
|
$312.55 K
|
$252.82 K
|
$80.42 K
|
| Weighted Average Shares Out Diluted |
$89.33 M
|
$704.61 M
|
$39.16 M
|
$30.86 M
|
$27.38 M
|
$17.75 M
|
$379.41 K
|
$312.55 K
|
$252.82 K
|
$80.42 K
|
| Link |
|
|
|
|
|
|
|
|
|
|
